Skip to main content
Premium Trial:

Request an Annual Quote

Perry Karsen

Intellia Therapeutics has named Perry Karsen the chairman of its board of directors.

Until January, Karsen was CEO of Celgene Cellular Therapeutics. Previously he served as COO and executive VP at Celgene, president and CEO of Pearl Therapeutics, and has held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech, and Abbott Laboratories.

Karsen also serves on the board OncoMed Pharmaceuticals, Voyager Therapeutics, Jounce Therapeutics, and Pliant Therapeutics. He holds an undergraduate degree in biology from the University of Illinois, Urbana-Champaign, a master's degree in biology education from Duke University, and a Master of Management degree from Northwestern University's Kellogg Graduate School of Management.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.